// App-Quantinova.ai

P065 : Evaluating the Efficacy and Safety of 6-Week Extended Interval Dosing of Natalizumab Via a Prospective, Controlled, Randomized Phase 3b Study

Researchers

Presenter

  • Jeffrey A Cohen

Principal Investigators

  • Nolan Campbell

  • Heinz Wiendl

  • John Foley

  • Helmut Butzkueven

  • Lana Zhovtis Ryerson

  • Gavin Giovannoni

  • Douglas L. Arnold

  • Gilles Defer

  • Joep Killestein

  • Gary R Cutter

  • Zheng Ren

  • Rachna Kasliwal

  • Giuseppina Stifano

  • Ih Chang

  • Pei-Ran Ho

Medical Centers

  • Cleveland Clinic, Cleveland, OH

  • Biogen, Cambridge, MA

  • University Hospital of Muenster, Muenster, Germany

  • Rocky Mountain MS Clinic, Salt Lake City, UT

  • Eastern Health Clinical School, Monash University, Melbourne, Australia

  • NYU Langone Health, New York University, New York, NY

  • Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK

  • Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada

  • Centre Hospitalier Universitaire Hotel-Dieu de Nantes, Nantes, France

  • MS Center Amsterdam, VU University Medical Center, Amsterdam, Netherlands

  • Univ of Alabama Sch of Public Health, Birmingham, AL

Locations

  • United States

  • Germany

  • Australia

  • United Kingdom

  • Canada

  • France

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Natalizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Pharmacodynamics

  • Double Blind/Blinded

  • Open Label

  • Prospective

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved